GLP-1 medicines copy a gut hormone that reduces appetite, and they do more for weight and metabolic health than any drug before them. They work on top of the basics, not in place of them: enough protein, regular resistance training, whole food, sleep and steady activity stay the foundation, and they are what protect muscle and hold the result. In large randomized trials semaglutide produced about 15% weight loss and tirzepatide about a fifth, both lowered long-term blood sugar by around two percentage points in type 2 diabetes, and semaglutide cut major cardiovascular events about a fifth in people who were overweight with heart disease and no diabetes.
They also carry trade-offs: gut side effects that are common early, some muscle lost along with the fat, and weight that returns when the drug stops, so they work best as ongoing treatment paired with enough protein and regular resistance training to protect muscle. They are prescription medicines, they are expensive, and whether one fits is a decision made with a prescriber. There is nothing to buy here.
Findings & Outcomes
What It Is
GLP-1 medicines are drugs that copy a natural gut hormone the body releases after a meal, one that signals fullness, slows the stomach, and helps the pancreas release insulin when blood sugar is high. The best known are semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management, and tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight, which acts on two gut-hormone receptors at once. Most are given as a weekly injection, and an oral form exists. They began as diabetes treatments and turned out to produce weight loss and heart protection well beyond earlier diabetes drugs.
These drugs act on the biology of appetite. Body weight is defended by hormonal systems that regulate hunger and fullness, and in many people those systems settle at a higher set point and strongly resist weight loss. The drugs act directly on that biology, which is why the results reach a scale that lifestyle programs alone have not matched. They are prescription medicines with a defined place in care, they are expensive, and they carry a set of trade-offs.
What It Does
Their proven effects fall into three groups, strongest and best-measured first.
The largest and most certain effect is weight. Both semaglutide and tirzepatide take off more body weight than any drug before them, measured directly in large randomized trials, and tirzepatide takes off more than semaglutide. In type 2 diabetes they also lower long-term blood sugar (HbA1c) substantially.
The second group is what those changes lead to over years. In people with diabetes or established heart disease, these drugs prevent heart attacks, strokes, and cardiovascular deaths, slow kidney disease, and lower the chance of dying from any cause. Semaglutide was the first GLP-1 drug shown to prevent cardiovascular events in people who were overweight and had heart disease but no diabetes.
The third group is newer. At the approved weekly dose, semaglutide now improves both the inflammation and the early scarring of metabolic liver disease, and trials are extending into obstructive sleep apnea and other conditions.
The same trials that show the benefits also record the costs: gut side effects, muscle lost along with the fat, and weight that returns when the drug stops.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Weight And Fat Loss
Semaglutide took off about 15% of body weight in obesity
People with obesity lost about 15% of their body weight over roughly sixteen months on weekly semaglutide, compared with about 2% on a dummy injection, and most lost at least 5%.
STEP 1 was a 68-week randomized, double-blind trial in 1,961 adults with a BMI of 30 or more (or 27 with a weight-related condition) and no diabetes, both arms receiving lifestyle counseling. Mean change in body weight was -14.9% with semaglutide 2.4 mg weekly versus -2.4% with placebo, a treatment difference of 12.4 percentage points. 86.4% of the semaglutide group lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%. Weight fell steadily over the titration period and then plateaued.
The study · 1
Wilding et al., once-weekly semaglutide in adults with overweight or obesity (STEP 1) · N Engl J Med 2021;384:989-1002
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Tirzepatide took off up to 20.9% of body weight at its top dose
On the highest dose of tirzepatide, people with obesity lost about a fifth of their body weight over eighteen months, more than the roughly 15% seen with semaglutide.
SURMOUNT-1 was a 72-week randomized, double-blind trial in 2,539 adults with obesity (or overweight with a complication) and no diabetes. Mean weight change was -15.0%, -19.5% and -20.9% at tirzepatide 5, 10 and 15 mg weekly versus -3.1% on placebo. Tirzepatide is a dual agonist acting on both the GLP-1 and the GIP receptor, and 57% of those on the 15 mg dose (50% at 10 mg) lost at least a fifth of their body weight.
The study · 1
Jastreboff et al., tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) · N Engl J Med 2022;387:205-216
About two-thirds of the lost weight returns within a year of stopping
After stopping semaglutide, people put back about two-thirds of the weight they had lost within a year, and their blood pressure and blood sugar drifted back toward where they started.
This extension followed 327 participants from STEP 1 for one year after both semaglutide and lifestyle intervention were withdrawn at week 68. Participants regained about two-thirds (11.6 percentage points of the 17.3% lost) of their prior weight loss by week 120, and cardiometabolic improvements including blood pressure and glycated hemoglobin similarly reverted toward baseline. The pattern reflects that the drug acts only while it is taken and does not reset the body's set point.
Because the effect depends on staying on the drug, plan from the outset for the long term, including cost and the habits that support the result.
The study · 1
Wilding et al., weight regain and cardiometabolic effects after withdrawal of semaglutide, the STEP 1 trial extension · Diabetes Obes Metab 2022;24:1553-1564
Blood Sugar
Both drugs cut HbA1c about 2 percentage points in type 2 diabetes
In type 2 diabetes, both drugs lowered long-term blood sugar (HbA1c) by around two percentage points, a large drop, with tirzepatide slightly ahead of semaglutide.
SURPASS-2 was a 40-week open-label randomized trial in 1,879 adults with type 2 diabetes inadequately controlled on metformin (mean baseline HbA1c 8.28%). HbA1c fell by 2.01, 2.24 and 2.30 percentage points on tirzepatide 5, 10 and 15 mg and by 1.86 on semaglutide 1 mg. Tirzepatide was non-inferior and superior to semaglutide at all three doses, and produced greater weight loss as well.
The study · 1
Frias et al., tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) · N Engl J Med 2021;385:503-515
Heart And Vascular
Semaglutide cut major cardiovascular events 20% in obesity without diabetes
In people who were overweight and already had heart disease but not diabetes, semaglutide lowered the rate of heart attacks, strokes and cardiovascular deaths by about a fifth over three years.
SELECT was a randomized, double-blind trial in 17,604 adults aged 45 or over who were overweight or obese and had established cardiovascular disease but not diabetes. Over a mean follow-up of 39.8 months, the primary composite endpoint occurred in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo (HR 0.80, 95% CI 0.72 to 0.90). This was the first trial to show a GLP-1 drug prevents cardiovascular events in people without diabetes, and the benefit appeared partly separable from the weight lost.
The study · 1
Lincoff et al., semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT) · N Engl J Med 2023;389:2221-2232
Semaglutide cut major cardiovascular events 26% in high-risk type 2 diabetes
In people with type 2 diabetes at high heart risk, semaglutide lowered heart attacks, strokes and cardiovascular deaths by about a quarter over two years.
SUSTAIN-6 was a 104-week randomized, double-blind pre-approval cardiovascular safety trial in 3,297 adults with type 2 diabetes at high cardiovascular risk. The primary composite occurred in 6.6% on semaglutide versus 8.9% on placebo (HR 0.74, 95% CI 0.58 to 0.95), driven mainly by a reduction in nonfatal stroke and nonfatal heart attack rather than cardiovascular death.
The study · 1
Marso et al., semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) · N Engl J Med 2016;375:1834-1844
Longevity And Mortality
GLP-1 drugs lowered death from any cause 12% in type 2 diabetes
Pooling the big diabetes heart-outcome trials, these drugs lowered the chance of dying from any cause by about 12%, and cut heart and kidney events as well.
This systematic review and meta-analysis pooled 8 randomized cardiovascular-outcome trials of GLP-1 receptor agonists in 60,080 adults with type 2 diabetes. All-cause mortality was reduced by 12% (HR 0.88, 95% CI 0.82 to 0.94), the three-point major adverse cardiovascular event composite by 14% (HR 0.86), and a composite kidney outcome by 21% (HR 0.79). Effects were broadly consistent across the individual drugs in the class.
The study · 1
Sattar et al., cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in type 2 diabetes, systematic review and meta-analysis · Lancet Diabetes Endocrinol 2021;9:653-662
Digestion
Nausea reached about 44% early on, and about 7% stopped the drug
Nausea is the most common side effect, reaching nearly half of people early on, along with diarrhea, vomiting and constipation. They are usually mild to moderate and fade as the body adjusts, though some people stop because of them.
In the STEP 1 obesity trial (1,961 adults, 68 weeks), gastrointestinal disorders were the most frequent adverse events with semaglutide 2.4 mg: nausea in about 44% versus 18% on placebo, with diarrhea, vomiting and constipation also raised. Most events were transient and mild to moderate, concentrated in the dose-escalation period. Discontinuation for adverse events was about 7% on semaglutide versus 3% on placebo, driven largely by gastrointestinal symptoms.
Raising the dose slowly, eating smaller meals, and stopping when full reduce the symptoms; severe or lasting symptoms are a reason to have the prescriber slow the pace or pause.
The study · 1
Wilding et al., once-weekly semaglutide in adults with overweight or obesity (STEP 1), adverse events · N Engl J Med 2021;384:989-1002
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Semaglutide 2.4 mg improved liver fibrosis in 36.8% versus 22.4% and resolved steatohepatitis in 62.9% versus 34.3%
In people with the inflammatory form of fatty liver disease and early scarring, semaglutide at the approved 2.4 mg weekly dose cleared the inflammation in about 63% versus 34% on placebo and improved the scarring in 36.8% versus 22.4%. An earlier trial at a lower daily dose had cleared the inflammation but not moved the scarring.
The phase 3 ESSENCE trial randomized 1,197 adults with biopsy-defined metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis stage F2 or F3 in a 2:1 ratio to once-weekly semaglutide 2.4 mg or placebo. At the prespecified week-72 interim analysis of the first 800 patients, reduction in liver fibrosis without worsening of steatohepatitis occurred in 36.8% on semaglutide versus 22.4% on placebo, and resolution of steatohepatitis without worsening of fibrosis in 62.9% versus 34.3%, both P<0.001; 32.7% achieved both. An earlier 72-week phase 2 trial in 320 adults, using a lower daily 0.4 mg dose, had resolved steatohepatitis in 59% versus 17% but had not significantly improved the fibrosis stage.
At the approved weekly dose, semaglutide now improves both the inflammation and the early scarring of MASH, so the liver benefit is one reason it may be considered when MASH occurs alongside obesity or type 2 diabetes, guided by a specialist. Whether it prevents cirrhosis and its complications is still being tested.
The studies · 2
Semaglutide in MASH with fibrosis, ESSENCE, NEJM 2025 · N Engl J Med 2025
Newsome et al., a placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis · N Engl J Med 2021;384:1113-1124
Kidney Disease
Semaglutide cut major kidney events 24% in diabetic kidney disease
In people with type 2 diabetes and existing kidney disease, semaglutide cut the chance of kidney failure and major kidney decline by about a quarter.
FLOW was a randomized, double-blind trial in 3,533 adults with type 2 diabetes and chronic kidney disease. The primary composite of major kidney disease events (onset of kidney failure, a sustained fall in eGFR of at least 50%, or death from kidney or cardiovascular causes) was reduced by 24% with semaglutide (HR 0.76, 95% CI 0.66 to 0.88). The trial was stopped early for efficacy, and semaglutide also reduced cardiovascular events and death from any cause.
The study · 1
Perkovic et al., effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW) · N Engl J Med 2024;391:109-121
Muscle And Strength
About a quarter of the weight lost is muscle, not fat
About a quarter of the weight lost on these drugs is muscle and other lean tissue rather than fat, similar to weight loss by other means. The body did not become proportionally less muscular, so the concern is the total muscle lost, which counts more as you age.
This meta-analysis pooled 22 randomized trials (2,258 participants) with body-composition measurement. GLP-1 receptor agonists reduced total body weight by about 7.8 lb (3.55 kg), with lean mass accounting for approximately 25% of the loss. Relative lean mass, expressed as percent change from baseline, was unaffected, indicating the body did not become proportionally less muscular. Liraglutide was the only agent to reduce weight without significantly cutting lean mass, while semaglutide and tirzepatide were the most effective for fat loss and among the least effective at preserving lean mass.
Enough protein and regular resistance training are the levers shown to protect muscle during weight loss, which is why they belong alongside the drug rather than after it, especially for older adults.
The study · 1
Effect of GLP-1 receptor agonists and co-agonists on body composition, network meta-analysis · Metabolism 2025
How It Works
These drugs work on three linked systems at once. In the brain, they act on appetite centers to reduce hunger and the urge to eat between meals, and people often describe the constant urge to eat easing. In the stomach, they slow the rate at which a meal empties, so fullness comes sooner and lasts longer and the rise in blood sugar after eating is gentler. In the pancreas, they raise insulin release in a glucose-dependent way, meaning mainly when blood sugar is high, which is why on their own they rarely drive sugar too low. For the metabolic system underneath all of this, see insulin and glucose handling.
Anatomy of the Practice
1The gut hormone they copy
GLP-1 is a hormone the gut releases after eating. It signals the pancreas to release insulin when blood sugar is high, slows the stomach, and acts on appetite centers in the brain to bring on fullness. These drugs are engineered copies that resist breakdown, so a single weekly injection keeps that signal going. Because they are proteins, they are destroyed if swallowed in ordinary form, which is why most are injected and the dose is raised in steps over weeks to let the gut adjust.
2The two-receptor drugs
Tirzepatide adds a second target, the GIP receptor, alongside GLP-1. GIP is another gut hormone involved in insulin release and fat handling. Acting on both appears to produce more weight loss than acting on GLP-1 alone, which is the leading explanation for tirzepatide reaching about a fifth of body weight where semaglutide reaches about 15%.
3Why appetite falls
The weight loss comes mainly through eating less, not through burning more. Slower stomach emptying means food stays longer and fullness comes sooner, and the brain signaling lowers hunger and the urge to eat between meals. Less food goes in, and the body draws on its own fat stores.
The Trade-offs and What Is Not Yet Known
Gut side effects are the most common cost, and they cluster in the first weeks while the dose is climbing: nausea, diarrhea, vomiting, and constipation. For most people they are mild to moderate and ease as the body adjusts, though a minority stop the drug because of them. Raising the dose slowly is the main lever that keeps them manageable.
Some of the weight lost is muscle, not fat, as with weight loss by any means. The proportion of the body that is lean tissue holds steady, so the concern is the absolute muscle lost, which counts more with age. Enough protein and regular resistance training are the levers shown to protect it, which is why they belong alongside the drug from the start.
The effect depends on staying on the drug. After stopping semaglutide, most of the lost weight returns within a year, and blood pressure and blood sugar drift back toward where they started. These are expensive medicines, and coverage varies a great deal, so the cost of staying on is part of the decision from the outset.
The weight and the metabolic gains return when the drug stops, so these are treatment for an ongoing condition, planned over years.
Some things are not settled. The longest trials run about three to four years, so the open questions are all about the long run:
- Decade-scale safety is not yet established.
- Most of the weight and heart evidence comes from people who were obese or already at high cardiovascular risk, so the size of the benefit in lower-risk, general use is less certain.
- On current evidence, few people can come off the drug and keep the result.
Using Them Well
There are no doses or product links here, because starting one is a medical decision. Below is what to raise with a prescriber and how to get the most from the treatment if you and your clinician decide it fits.
Whole food, steady activity, sleep, and enough protein with regular resistance training are the foundation of weight and metabolic health, and the drug works on top of them, not in their place. These habits protect muscle and support the result whether or not you stay on the medicine, which is why they come first and continue alongside it.
Whether one fits depends on your weight, your blood sugar, your heart and kidney health, and your other conditions and medicines. A clinician sets the starting dose, raises it in steps, and monitors how you respond. That conversation is also where cost and access get worked out, since these drugs are expensive and coverage varies widely. Product bought outside a pharmacy carries no check on what is in the vial.
A share of the weight lost is muscle, and older adults especially should protect it. Enough protein and regular resistance work are the two levers shown to preserve muscle during weight loss. See [protein and muscle](/go/integrative/practice/protein-and-muscle) for the daily amount and [resistance training](/go/integrative/practice/resistance-training) for the minimum effective dose.
Nausea and other gut symptoms are worst in the first weeks and while the dose is climbing, and for most people they settle. Eating smaller meals, slowing down, and stopping when full tend to help. If they are severe or lasting, the prescriber can slow the pace or pause the increase.
Weight and the metabolic gains tend to return after stopping, so these are ongoing treatment for a chronic condition. Think from the outset about the plan over years, the cost of staying on, and the eating and training habits that support the result whether or not you stay on the drug.
Go Deeper
- Type 2 diabetes: where these drugs change long-term outcomes, alongside the lifestyle levers that put early diabetes into remission.
- Weight and metabolic health: the whole picture of fat loss, where these drugs sit after the basics of training, protein and whole food.
- Peptides: the wider peptide market, where the GLP-1 drugs are the approved, tested end and most of the rest is not.
- Protein and muscle: the daily protein that protects muscle during weight loss.
- Resistance training: the other half of protecting muscle, and the best-supported practice in this whole section.
The Chinese Medicine View
These are modern drugs, isolated and engineered in the last few decades, so there is no classical Chinese entry for any of them. No historical text assigns a channel, a temperature or a flavor to a GLP-1 medicine, and no traditional formula contains one. What follows places them against the tradition as a lens, not as evidence, and it borrows no classical claim, because none exists.
These drugs act on functions Chinese medicine has always reasoned about. The Spleen, in this framework, governs the transformation and transport of food into usable substance, and the Spleen and Stomach together are read as the seat of appetite, fullness and digestion. When that function is weak, the tradition describes food and fluid failing to move and transform, gathering instead as Dampness and Phlegm, patterns often laid over the modern picture of carrying excess weight with a sluggish metabolism. A drug that slows the stomach, reduces appetite and shifts how the body handles what it takes in is, in a loose sense, acting on the same functions the tradition assigns to the Spleen and Stomach.
The tradition would also draw a distinction. Reducing appetite is not the same as strengthening the organ that governs it, and Chinese medicine reads persistent poor appetite, early fullness and fatigue after eating as signs of a depleted Spleen, not a goal to aim for. So the framework would see these drugs as acting on the symptom-level picture while leaving its own aim, a Spleen that transports well on its own, as separate work, which is one reading of why the weight returns when the drug stops. This is a way of relating a modern category to a tradition, not a claim that Chinese medicine explains or endorses these drugs, and not a suggestion that any herb or formula substitutes for them. The evidence for the drugs stands on the trials, which are large and consistent.
Cautions For These Medications
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
GLP-1 drugs raised gallbladder and biliary disease about a third
This systematic review and meta-analysis pooled 76 randomized trials (103,371 patients, mean age 57.8, 40.5% women). Randomization to a GLP-1 receptor agonist was associated with a 37% higher risk of gallbladder or biliary disease (RR 1.37, 95% CI 1.23 to 1.52), including cholelithiasis (RR 1.27) and cholecystitis (RR 1.36). Risk was higher at higher doses (RR 1.56) and with longer treatment, and was greatest in weight-loss trials (RR 2.29) versus diabetes trials (RR 1.27), consistent with rapid weight loss being part of the mechanism. The trials reported relative risks without a clean absolute figure.He et al., association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases, systematic review and meta-analysis of randomized clinical trials
These are prescription medicines, and the starting decision sits with a clinician
Whether one fits, at what dose, and how fast to raise it depends on your full picture: blood sugar, heart and kidney health, other conditions and other medicines. Starting, changing or stopping one belongs with the prescriber who follows you. Compounded or gray-market versions sold outside a pharmacy carry no check on what is actually in the vial, and dosing errors with them have caused harm.
Not in pregnancy or when trying to conceive
These drugs are not recommended in pregnancy, and guidance is to stop them well before a planned pregnancy because they clear slowly. Anyone who could become pregnant should discuss contraception and timing with a prescriber, and because appetite suppression can reduce how well the pill is absorbed early on, a backup method is often advised. Rapid weight loss around conception is itself a reason for medical guidance.
Gallbladder, biliary and pancreas
Across randomized trials these drugs raise the risk of gallbladder and biliary disease by about a third, more at higher doses and in weight-loss use, partly a consequence of rapid weight loss itself. Pancreatitis has been reported as well. Severe, persistent abdominal pain, especially with vomiting, is a reason to seek care promptly; do not wait it out.
A thyroid contraindication for some families
In rodent studies these drugs caused thyroid C-cell tumors. That has not been shown in people, but they carry a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or the genetic syndrome MEN 2. Raise that history before starting.
Severe or lasting gut symptoms
Nausea, vomiting, diarrhea and constipation are the usual side effects and are most common in the first weeks and while the dose climbs. For most people they are mild to moderate and ease with time and a slower increase. If they are severe or lead to dehydration, the prescriber should adjust the plan.
Tell your team before surgery or an endoscopy
Because these drugs slow how fast the stomach empties, food can remain in the stomach longer than expected, which raises the risk of breathing stomach contents into the lungs under sedation or general anesthesia. Anesthesiology guidance now asks that the prescriber and the procedure team know you take one, so they can decide whether to hold a dose or take extra precautions before an operation or an endoscopy. Do not stop on your own, but do make sure they know.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
How much weight do people lose on GLP-1 medicines?
In large randomized trials, adults with obesity lost about 15% of their body weight over roughly sixteen months on weekly semaglutide, against about 2% on a dummy injection, and about a fifth on the highest dose of tirzepatide. These are averages, so individual results vary widely, and the loss builds gradually as the dose is raised. The figures come from people without diabetes; in type 2 diabetes the weight loss tends to be somewhat smaller.
Do these drugs help the heart, or only weight?
They do more than reduce weight. In people who were overweight and had heart disease but not diabetes, semaglutide cut major cardiovascular events, meaning heart attack, stroke and cardiovascular death, by about a fifth over roughly three years. In type 2 diabetes, semaglutide also reduced cardiovascular events, pooled data across the class point to lower overall death rates, and semaglutide slowed kidney disease in people who already had it. These heart, kidney and survival benefits are why the drugs are used for more than weight loss.
What happens if I stop taking one?
Weight and much of the metabolic improvement tend to return. In the extension of the semaglutide weight trial, people regained about two-thirds of the weight they had lost within a year of stopping, and blood pressure and blood-sugar markers drifted back toward where they started. That pattern is why these are best understood as treatment for an ongoing condition, and it is the strongest reason to build the eating and training habits that support the result alongside the drug.
Will I lose muscle on a GLP-1 medicine?
Some. When the body loses a large amount of weight, a share of it is muscle, not fat, and pooled trial data put that share at about a quarter of the total, similar to weight loss by other means. The proportion of the body that was lean tissue held steady, so this tracks the total weight lost. Enough protein and regular resistance training are the tools shown to protect muscle, which is why they belong alongside the medicine.
Are GLP-1 medicines a cure for type 2 diabetes?
They are a strong treatment, not a cure. They lower blood sugar substantially, by around two percentage points of HbA1c in head-to-head trials, and they improve heart and kidney outcomes over years. But blood sugar tends to rise again if the drug stops, and early type 2 diabetes can sometimes reach remission through weight loss itself. These work best as part of care that includes the lifestyle levers on the type 2 diabetes page, guided by the person who prescribes them.
They are expensive. Are compounded or online versions the same thing?
Not reliably. Brand-name semaglutide and tirzepatide are costly and coverage varies, which has driven a large market in compounded and online versions. Those are not held to the same manufacturing checks, the actual contents and concentration can differ from the label, and dosing errors with them have sent people to the hospital. If cost is the barrier, that is a conversation to have with a prescriber about approved options and access programs, not a reason to buy from an unverified source.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 13 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.